Immunohaematology – the history, current knowledge and the role of The Institute of Haematology and Blood Transfusion in Prague

Česká verzia

Authors: M. Písačka; P. Kořínková; E. Matějková; H. T. Bolcková
Authors place of work: Ústav hematologie a krevní transfuze Praha, ředitel prof. MUDr. Marek Trněný, CSc.
Published in the journal: Vnitř Lék 2012; 58(Suppl 2): 103-114
Category:

Summary

Immunohaematology is a branch of the medical science dealing with interactions of the immune system and blood, namely with the detection of blood cells antigens and related antibodies. The discovery of immunohaematology principles in the beginning of 20th century has broken the immune barrier of the blood transfusion and enabled the progress in the transfusion medicine and in all other medical disciplines requiring the transfusion support. Routine use of immunohaematology tests serves for the assurance of compatible blood transfusions and for the diagnostics, monitoring and treatment of allo- and autoimmune cytopenias. So far more than 300 red cell antigens are known (32 blood group systems, several collections and 2 series) together with dozens of thrombocyte and leucocyte antigens and with large HLA system, where immunohaematology borders with the transplantation immunology. In this review we present the history of immunohaematology and the list of diagnostic methods used in this field. Important contribution to the progress of Czechoslovak and later Czech immunohaematology was brought by the immunohaematology department of the Institute of Haematology and Blood Transfusion (ÚHKT), namely by the Reference Laboratory for Immunohaematology (RLI), which serves as a center for specialized laboratory testing and consultation, new methods introduction, proficiency testing schemes organization and international immunohaematology cooperation. Some of results published by the RLI experts have impact on the general immunohaematology knowledge.

Key words:
immunohaematology – blood cells antigens – blood groups: systems, collections, series – antibodies – compatible transfusion – Reference Laboratory for Immunohaematology in ÚHKT

Zdroje

1. Landsteiner K. Zur Kenntnis der antifermentativen, lytischen und agglutinietenden Wirkungen des Blut-serums und der Lymphe. Zentralbl Bakt 1900; 27: 357–366.

2. Helias V, Saison C, Ballif BA et al. ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis. Nat Genet 2012; 44: 170–173.

3. Saison C, Helias V, Ballif BA et al. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nat Genet 2012; 44: 174–177.

4. Landsteiner K. Uber Agglutinationserscheinungen normalen menschlichen Blutes. Wien Klin Wochenschr 1901; 14: 1132–1134.

5. von Decastello A, Sturli A. Uber die Isoagglutinine im Serum gesunder und kranker Menschen. Munchen Med Wochenschr 1902; 49: 1090–1095.

6. Landsteiner K, Levine P. Further observations on individual differences of human blood. Proc Soc Exp Biol NY 1927; 24: 941–942.

7. Levine P, Stetson RE. An unusual case of intra-group agglutination. JAMA 1939; 113: 126–127.

8. Landsteiner K, Wiener AS. An agglutinable factor in human blood recognized by immune sera for Rhesus blood. Proc Soc Exp Biol NY 1940; 43: 223–224.

9. Callender S, Race RR, Paykoc ZV. Hypersensitivity to transfused blood. Br Med J 1945; 2: 83–84.

10. Coombs RR, Mourant AE, Race RR. In-vivo isosensitisation of red cells in babies with haemolytic disease. Lancet 1946; 1: 264–266.

11. Mourant AE. A new human blood group antigen of frequent occurrence. Nature 1946; 158: 237–238.

12. Cutbush M, Mollison PL. The Duffy blood group system. Heredity 1950; 4: 383–389.

13. Allen FH, Diamond LK, Niedziela B. A new blood-group antigen. Nature 1951; 167: 482.

14. Daniels G. Human Blood Groups. 2nd ed. Oxford: Blackwell Science Ltd 2002.

15. Reid M, Lomas-Francis C. The Blood Group Antigen FactsBook. 2nd ed. London: Elsevier Ltd 2004.

16. Hult AK, Svensson L, Stamps R et al. Forssman expression on human red cells: biochemical and genetic basis of a novel histo-blood group system candidate. Transfusion 2011; 51 (Suppl): 1A.

17. Harrington WJ, Sprague CC, Minnich V et al. Immunologic mechanism in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38: 433–469.

18. Dausset J. Iso-leuko-anticorps. Acta Haematol 1958; 20: 156–166.

19. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998–1000.

20. Buc M, Ferenčík M. Imunogenetika. Bratislava: Alfa plus 1994.

21. Rodey GE. HLA Beyond Tears. 2nd ed. Colorado: De Novo Inc 2000.

22. Thorsby E. A short history of HLA. Tissue Antigens 2009; 74: 101–116.

23. Narinder K Mehra. The HLA Complex in Biology and Medicine: A Resource Book. Darya Ganj: Jaypee Brothers Medical Publishers Ltd 2010.

24. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973; 136: 409–416.

25. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286–1292.

26. Warkertin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011; 9 (Suppl 1): 105–117.

27. Warkentin TE, Sheppard JA, Moore JC et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963–4969.

28. Greinacher A, Kohlmann T, Strobel U et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970–4976.

29. Warkertin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1–7.

30. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27–30.

31. Greinacher A, Michels I, Kiefel V et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734–736.

32. Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program 2011; 2011: 143–149.

33. Amiral J, Peynaud-Debayle E, Wolf M et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996; 52: 90–95.

34. Warkentin TE, Sheppard JI, Horsewood P et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703–1708.

35. Warkentin TE, Sheppard JA, Moore JC et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146: 341–346.

36. Greinacher A, Eichler P, Lietz T et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005; 106: 2921–2922.

37. Backhoul T, Griptner A, Najaoui A et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 1260–1265.

38. Greinacher A, Ittermann T, Bagemühl J et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 2010; 8: 2025–2031.

39. Bakchoul T, Giptner A, Najaoui A et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 1260–1265.

40. Pisacka M, Kralova M, Vytiskova J et al. Group A or 0? Discrepancy in AB0 grouping caused by monoclonal anti-A cross-reacting with Tn polyaglutinable red cells. Vox Sanguinis 2008; 95 (Suppl 1): 173–174.

41. Storry JR, Pisacka M, Pejchalova A et al. Heterozygosity for consensus FUT1 associated with a new ABH phenotype challenging current dogma: H-negative group A and B. Vox Sanguinis 2010; 99 (Suppl 1): 379–380.

42. Pisacka M, Poole J, Rodrigues M et al. Serological Basis of a New Variant Glycophorin. 24th World Congress of ISBT in Tokyo, Japan. Tokyo: Makuhari Messe 1996.Abstract 147.

43. Poole J, Bruce LJ, Tanner MJ et al. Novel molecular basis for the Hil (MNS20) antigen. Transfusion 1998; 38 (Suppl): 103S.

44. Avent ND, Liu W, Jones JW et al. Molecular analysis of Rh transcripts and polypeptides from individuals expressing the DVI variant phenotype: an RHD gene deletion event does not generate All DVIccEe phenotype. Blood 1997; 89: 1779–1786.

45. Pisacka M, Vytiskova J, Hejna J et al. A new variant of Rh(D) antigen – revealed by reactions of anti-ep12 monoclonal antibodies and lacking exon 5 D-specific reaction of exon-scanning RHD/CE PCR-SSP. Vox Sanguinis 1998; 74: 1332.

46. Flegel WA, von Zabern I, Doescher A et al. DCS-1, DCS-2 and DFV share amino acid substitutions at the extracellular RhD protein vestibule. Transfusion 2008; 48: 25–33.

47. Flegel WA, von Zabern I, Doescher A et al. D variants at the RhD vestibule in the weak D type 4 and Eurasian D clusters. Transfusion 2009; 49: 1059–1069.

48. Pisacka M. Three new RHD genotypes found in Czech population in 2009 – single point mutations in exon 1 /48G>C/ and exon 5 /787G>A/ and hybrid gene RHD(1/8)-CE(9)-D(10). Vox Sanguinis 2010; 99 (Suppl 1): 83.

49. Pisacka M, Vytiskova J, Kralova M et al. Atypical pattern of a partial/weak D case: DFR-like serology but D cat III type 7 PCR-SSP. Transfusion 2010; 50 (Suppl): 147–148.

50. Pisacka M,Vytiskova J, Kralova M et al. Immunogenic potential of RhD variant RoHar. Vox Sanguinis 2005; 89: 148.

51. Pisacka M, Vytiskova J, Kralova M et al. Variant D antigens and weak D types in the Czech Republic. Transfusion 2005; 45: 120A.

52. Pisacka M, Kralova M, Galuszkova D et al. First Czech case of K(null) phenotype – serologic characteristics and genetic basis. Vox Sanguinis 2007; 93 (Suppl 2): 64–65.

53. Klempir J, Roth J, Zarubova K et al. The McLeod syndrome without acanthocytes. Parkinsonism Relat Disord 2008; 14: 364–366.

54. Pisacka M, Suttnar J, Stambergova M. Activation of Thomsen-Friedenreich Antigen Causing False Positive Antigen Typing with Monoclonal Anti-Le(a). XXIIIrd ISBT Congress Amsterdam 1994 – abstract. Vox Sanguinis 1994; 67: 73.

55. Libich M, Kout M, Giles CM. Fy(a-b-) phenotype in Czechoslovakia. Vox Sang 1978; 35: 423–425.

56. Pisacka M, Vytiskova J, Latinakova A et al. Molecular background of the Fy(a-b-) phenotype in gypsy population living in the Czech and Slovak Republic. Transfusion 2001; 41: 15S.

57. Kornstad L, Kout M, Larsen AM et al. A rare blood group antigen, Jna. Vox Sang 1967; 13: 165–170.

58. Jarolim P, Rubin HL, Zakova D et al. Characterization of seven low incidence blood group antigens carried by erythrocyte band 3 protein. Blood 1998; 92: 4836–4843.

59. Banzetova H, Bystricka D, Cerna O et al. First finding of Gy(a-) phenotype in the Czech Republic since its discovery in 1967. Possible relationship to original probands found in the USA in 1967–1968. Vox Sanguinis 2006; 91: 102–103.

60. Pisacka M, Kralova M, Prochazkova R. Anti-Ge antibodies – enormous titre increase and mild acute reaction after transfusion of crossmatch negative units. Transfusion 2007; 47 (Suppl): 166A.

61. Pisacka M, Prosicka M, Kralova M et al. Six cases of anti-Jr(a) antibody detected in one year – a probable relation with gipsy ethnic minority from Central Slovakia. Vox Sang 2000; 78: P146.

62. Pisacka M, Kralova M, Kucerakova M. Anti-Vel missed in IgG-based solid phase test. Transfusion 2009. Ahead of print.

63. Avent N, Martinez A, Flegel W et al. The Bloodgen Project: towards mass scale genotyping for human blood group antigens. Vox Sanguinis 2006; 91 (Suppl 3): 33–34.

64. Majsky A. Die verwendung von formalinisierten trombozyten als antigen für den nachweis von trombozytenantikörpern mittels des agglutinationstestes, derkomplement-bindungsreaktion und der antihumanglobulin-ablenkungsmethode. Z Ges Inn Med 1960; 15: 1117–1122.

65. Kořínková P, Majský A. Moderní metody v imunologii krevních destiček. Vnitř Lék 1985; 31: 795–801.

66. Kořínková P, Suttnar J, Vytisková J et al. Fetomaternální aloimunní trombocytopenie – možnosti diagnózy a transfuzní léčby. Česk Gynekol 1999; 64: 28–31.

67. Kořínková P, Holada K, Dyr JE. Aloimunní novorozenecká trombocytopenie způsobená anti-PlA1 trombocytární protilátkou. Česk Pediatr 1990; 45: 399–401.

68. Korínková P, Vorlícek J, Majský A. A study of granulocyte cytotoxins and detection of granulocyte allospecific antigens. Transfusion 1982; 22: 379–383.

69. Majsky A. Einige Bemerkungen zu den HL-A-Antigen und ihrer Bestimmung. Folia Haematol Leipzig 1947; 101: 608–614.

70. Bláhová K, Bielaszewská M, Stejskal J et al. Hemolyticko-uremický syndrom. Praha: Triton 2000.